Follicular Lymphoma
Conference Coverage
Novel SYK inhibitor shows ‘good early evidence’ of activity
LUGANO—The phase 1, first-in-human study of the novel SYK inhibitor TAK-659 is showing “good early evidence” of antitumor activity in patients...
News
Early relapse signals high mortality in follicular lymphoma
Key clinical point: Patients with follicular lymphoma who relapse within 2 years of receiving R-CHOP are at high risk of death, unlike those who...
Conference Coverage
‘Radically different’ PI3Kδ inhibitor lacks hepatotoxicity
Photo by Larry Young LUGANO—Updated phase 1 results with TGR-1202 suggest this next-generation PI3kδ inhibitor lacks the hepatotoxicity associated...
News
P13K inhibitors TGR-1202, duvelisib found clinically active in CLL
Key clinical point: The investigational P13K inhibitors TGR-1202 and duvelisib were clinically active in phase I trials. Major finding: TGR-1202...
Conference Coverage
Targeted agent shows early promise for NHL
follicular lymphoma LUGANO—An anti-CD37 antibody-radionuclide conjugate provides sustained efficacy and a manageable safety profile in patients...
Conference Coverage
EZH2 inhibitor proves active in rel/ref NHL
LUGANO—The EZH2 inhibitor tazemetostat (EPZ-6438) has shown “meaningful clinical activity” as monotherapy in patients with advanced non-Hodgkin...
Conference Coverage
CAR T-cell therapy seems feasible for NHL, MM
©ASCO/Rodney White CHICAGO—The CD19-directed chimeric antigen receptor (CAR) T-cell therapy CTL019 has shown promise for treating non-Hodgkin...
News
Prenatal test can detect lymphoma in mothers
Photo by Graham Colm GLASGOW—A non-invasive prenatal test (NIPT) used to identify chromosomal fetal disorders can detect maternal cancers before...
Conference Coverage
Drug prolongs PFS in indolent, refractory NHL
the 2015 ASCO Annual Meeting CHICAGO—Adding obinutuzumab to treatment with bendamustine improves progression-free survival (PFS) in patients with...
News
GADOLIN: Combination improves PFS in rituximab-refractory indolent NHL
Key clinical point: Adding obinutuzumab to bendamustine extended progression-free survival in patients with rituximab-refractory indolent non-...